HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB: HSTC) today announced that it has targeted Ecuador for development of a Clinical Treatment Facility.
As the acceptance of integrative science-based cancer treatments worldwide continues to grow, so has HST Global, Inc.’s strategy of opening our own brand of Cancer Treatment Centers. To further facilitate this approach, HST Global is relying on international markets to reach a worldwide population. HST feels Ecuador will provide a significant platform to benefit patients on a global scale.
Mr. Ron Howell, CEO and President of HST Global Inc., stated, “We are impressed with the demographic diversity and economic infrastructure that Ecuador has developed. They have built world-class facilities that offer cutting edge technologies that complement our clinical protocols. We are in the initial phases of developing our entry strategy for Ecuador through relationships we have developed worldwide. These global partners will allow HST to leverage itself and align its resources in an effort to develop an Ecuadorian facility.”
Wes Tate, CFO, stated “I am pleased we are now in a position to move forward with our international expansion into Ecuador. As a company, we continue to seek opportunities to mature our corporate strategy and benefit the global community while also serving to substantiate shareholder value.”
About HST Global, Inc.
HST Global, Inc. is an Integrated Biotechnology Health and Wellness company that is developing and or acquiring a network of Wellness Centers worldwide that are primarily focused on the immunotherapy and alternative treatment of late stage cancer. In addition, the company intends to acquire innovative products for the treatment of late stage cancer. In this regard, the company primarily focuses on immunotherapy and alternative product candidates that are undergoing or have already completed significant clinical testing for the treatment of late stage cancer.
HST Global, Inc. wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.